Display options
Share it on

J Clin Diagn Res. 2017 Mar;11(3):ZC46-ZC50. doi: 10.7860/JCDR/2017/23975.9571. Epub 2017 Mar 01.

A Randomized Placebo- Controlled Double Blind Clinical Trial of Quercetin in the Prevention and Treatment of Chemotherapy-Induced Oral Mucositis.

Journal of clinical and diagnostic research : JCDR

Mohammad Mahdi Kooshyar, Pegah Mosannen Mozafari, Maryam Amirchaghmaghi, Atessa Pakfetrat, Parisa Karoos, Mahdokht Rashed Mohasel, Hosein Orafai, Amir Abbas Azarian

Affiliations

  1. Associate Professor, Department of Hematology and Oncology, Imam Reza Hospital, Mashhad University of Medicals, Mashhad, Khorasan Razavi, Iran.
  2. Associate Professor, Department of Oral and Maxillofacial Diseases Research Center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
  3. Professor, Department of Oral and Maxillofacial Diseases Research Center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
  4. General Dentist, Hojjati Dentistry Clinic, Mashhad, Khorasan Razavi, Iran.
  5. Oral and Maxillofacial Medicine Specialist, Department of Pedodontics and Oral Medicine, North Khorasan University of Medical Sciences, Mashhad, Iran.
  6. Professor, Department of Industrial Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Khorasan Razavi, Iran.
  7. PhD Candidate of Statistics, Statistics Office, Mashhad University of Statistics, Mashhad, Iran.

PMID: 28511508 PMCID: PMC5427434 DOI: 10.7860/JCDR/2017/23975.9571

Abstract

INTRODUCTION: Oral Mucositis (OM) is a serious complication of chemotherapy that results in painful debilitating inflammation that sometimes ends in interruption of treatment.

AIM: The study evaluated the effect of quercetin (a natural flavonoid) on preventing and treating chemotherapy induced OM in patients with blood malignancies.

RESULTS: Nine out of 20 patients developed OM (three in the intervention group and six in the control group). The incidence of OM was lower in the intervention group although it was not statistically significant (p=0.189). The mean severity of OM was higher in the intervention group (2.6 vs 2). Healing time, age, gender, type of malignancy, drug type and duration of OM were not different in two groups.

CONCLUSION: The incidence of mucositis was lower in the quercetin group, but mucositis was more severe in the intervention group, which may be due to lower oral health status in the intervention group.

Keywords: Cancer; Flavonoids; Haematologic malignancies

References

  1. Biochem Pharmacol. 2008 Jul 1;76(1):70-8 - PubMed
  2. Adv Skin Wound Care. 2012 Jan;25(1):23-8 - PubMed
  3. Jpn J Pharmacol. 1998 Dec;78(4):435-41 - PubMed
  4. Ann Oncol. 2011 Sep;22 Suppl 6:vi78-84 - PubMed
  5. Radiother Oncol. 1995 Mar;34(3):171-8 - PubMed
  6. Eur J Pharmacol. 2008 May 13;585(2-3):325-37 - PubMed
  7. Cochrane Database Syst Rev. 2010 Dec 08;(12):CD000978 - PubMed
  8. Food Chem Toxicol. 2010 Nov;48(11):3246-61 - PubMed
  9. Cochrane Database Syst Rev. 2011 Apr 13;(4):CD000978 - PubMed
  10. Lik Sprava. 2003 Jan-Feb;(1):96-9 - PubMed
  11. Support Care Cancer. 2000 Jan;8(1):55-8 - PubMed
  12. Mol Biol Rep. 2009 Sep;36(7):1825-32 - PubMed
  13. Interdiscip Toxicol. 2013 Mar;6(1):9-12 - PubMed
  14. Nutr Res Pract. 2011 Feb;5(1):28-33 - PubMed
  15. J Cell Biochem. 2009 Jan 1;106(1):73-82 - PubMed
  16. Food Chem Toxicol. 2007 Nov;45(11):2179-205 - PubMed
  17. Support Care Cancer. 2013 Jan;21(1):343-55 - PubMed
  18. J Pharm Bioallied Sci. 2011 Jul;3(3):361-7 - PubMed
  19. Int J Oral Maxillofac Surg. 2012 Feb;41(2):225-38 - PubMed
  20. J Contemp Dent Pract. 2010 Jul 01;11(4):E009-16 - PubMed
  21. Eur Rev Med Pharmacol Sci. 2011 Apr;15(4):406-12 - PubMed
  22. Mol Pain. 2013 Oct 23;9:53 - PubMed
  23. Nutrition. 2008 Jul-Aug;24(7-8):703-10 - PubMed
  24. Eur J Cancer. 2001 Nov;37(16):2056-63 - PubMed
  25. Support Care Cancer. 2013 Jan;21(1):327-32 - PubMed
  26. Support Care Cancer. 2013 Jan;21(1):333-41 - PubMed
  27. Arch Iran Med. 2012 Jul;15(7):413-7 - PubMed
  28. J Prosthet Dent. 1991 Sep;66(3):361-9 - PubMed
  29. Int J Cancer. 2010 Oct 15;127(8):1984-90 - PubMed
  30. J Pediatr Oncol Nurs. 2004 Jan;21(1):33-9 - PubMed
  31. Z Naturforsch C J Biosci. 1998 Jan-Feb;53(1-2):82-8 - PubMed
  32. Oral Oncol. 2013 Feb;49(2):102-7 - PubMed
  33. J Contemp Dent Pract. 2008 Mar 01;9(3):40-7 - PubMed
  34. Oncol Nurs Forum. 1996 Jul;23(6):921-7 - PubMed
  35. Life Sci. 2010 Feb 27;86(9-10):315-21 - PubMed
  36. Phytother Res. 2009 Feb;23(2):274-8 - PubMed
  37. Biomaterials. 2012 Apr;33(10):2991-3001 - PubMed
  38. Semin Radiat Oncol. 2009 Jan;19(1):29-34 - PubMed
  39. Korean J Physiol Pharmacol. 2009 Aug;13(4):295-300 - PubMed
  40. Arch Pharm Res. 2011 Sep;34(9):1527-34 - PubMed
  41. Life Sci. 2010 Sep 11;87(11-12):333-8 - PubMed
  42. Spec Care Dentist. 1998 Sep-Oct;18(5):189-93 - PubMed
  43. Eur J Cancer. 2004 May;40(8):1208-16 - PubMed
  44. Oral Surg Oral Med Oral Pathol. 1991 Mar;71(3):288-93 - PubMed
  45. J Dent Res Dent Clin Dent Prospects. 2015 Winter;9(1):23-8 - PubMed
  46. Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):275-9 - PubMed

Publication Types